Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07614321 · ClinicalTrials.gov registry record · Phase 4
Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis
A Phase 4 study, sponsored by Atlantic Health System.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT07614321 is a Phase 4 study that is actively recruiting participants, run by Atlantic Health System. The registered enrollment target is 60 participants.
The verdict
NCT07614321, a Phase 4 study, is actively recruiting participants, sponsored by Atlantic Health System.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters. The main questions it aims to answer are: Does silodosin improve lower urinary tract symptoms based on questionnaires? Does silodosin change Uroflowmetry parameters in female patients with MS? Researchers will compare silodosin to a placebo (a look-alike substance that contains no drug) to see if silodosin works to treat LUTS in female patients with MS. Participants will: Take silodosin or a placebo every day for 8 weeks Visit the clinic before initiating the medication and after 8 weeks of taking the medication for questionnaires and tests
Interventions
- DRUG Placebo
- DRUG Silodosin 8 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-04 |
| Est. Completion | 2028-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07614321
The ClinicalTrials.gov registry entry for NCT07614321 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atlantic Health System, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07614321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07614321 about?
NCT07614321 is a clinical study titled "Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis". The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters. The main questions it aims to answer are: Does silodosin improve lower ...
What is the current status of trial NCT07614321?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2026-04. Estimated completion is 2028-04.
What interventions are being tested in trial NCT07614321?
The interventions under investigation include: Placebo (DRUG), Silodosin 8 mg (DRUG).
Who is sponsoring clinical trial NCT07614321?
This trial is sponsored by Atlantic Health System, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.